This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): CNTO 328
Description: CNTO 328 is a chimeric (made from human and mouse proteins) high affinity monoclonal antibody that neutralizes interleuikin-6 (IL-6). By inhibiting IL-6, CNTO 328 works by blocking inflammation and tumor growth.
Deal Structure: CNTO 328 is being developed by Centocor, part of the Johnson & Johnson family of companies.
Additional information available to subscribers only: